1. Hepatic β-arrestin 2 is essential for maintaining euglycemia. Zhu L, Rossi M, Cui Y, Lee RJ, Sakamoto W, Perry NA, Urs NM, Caron MG, Gurevich VV, Godlewski G, Kunos G, Chen M, Chen W, Wess J (2017) J Clin Invest 127(8): 2941-2945
    › Primary publication · 28650340 (PubMed) · PMC5531395 (PubMed Central)
  2. Functional role of the three conserved cysteines in the N domain of visual arrestin-1. Vishnivetskiy SA, Lee RJ, Zhou XE, Franz A, Xu Q, Xu HE, Gurevich VV (2017) J Biol Chem 292(30): 12496-12502
    › Primary publication · 28536260 (PubMed) · PMC5535024 (PubMed Central)
  3. Differential manipulation of arrestin-3 binding to basal and agonist-activated G protein-coupled receptors. Prokop S, Perry NA, Vishnivetskiy SA, Toth AD, Inoue A, Milligan G, Iverson TM, Hunyady L, Gurevich VV (2017) Cell Signal : 98-107
    › Primary publication · 28461104 (PubMed) · PMC5797668 (PubMed Central)
  4. C-terminal motif of human neuropeptide Y receptor determines internalization and arrestin recruitment. Wanka L, Babilon S, Burkert K, Mörl K, Gurevich VV, Beck-Sickinger AG (2017) Cell Signal : 233-239
    › Primary publication · 27818291 (PubMed) · PMC5797669 (PubMed Central)
  5. Arrestin-2 and arrestin-3 differentially modulate locomotor responses and sensitization to amphetamine. Zurkovsky L, Sedaghat K, Ahmed MR, Gurevich VV, Gurevich EV (2017) Neuropharmacology : 20-29
    › Primary publication · 28419873 (PubMed) · PMC5859313 (PubMed Central)
  6. A Novel Dominant Mutation in SAG, the Arrestin-1 Gene, Is a Common Cause of Retinitis Pigmentosa in Hispanic Families in the Southwestern United States. Sullivan LS, Bowne SJ, Koboldt DC, Cadena EL, Heckenlively JR, Branham KE, Wheaton DH, Jones KD, Ruiz RS, Pennesi ME, Yang P, Davis-Boozer D, Northrup H, Gurevich VV, Chen R, Xu M, Li Y, Birch DG, Daiger SP (2017) Invest Ophthalmol Vis Sci 58(5): 2774-2784
    › Primary publication · 28549094 (PubMed) · PMC5455168 (PubMed Central)
  7. Peptide mini-scaffold facilitates JNK3 activation in cells. Zhan X, Stoy H, Kaoud TS, Perry NA, Chen Q, Perez A, Els-Heindl S, Slagis JV, Iverson TM, Beck-Sickinger AG, Gurevich EV, Dalby KN, Gurevich VV (2016) Sci Rep : 21025
    › Primary publication · 26868142 (PubMed) · PMC4751492 (PubMed Central)
  8. Paradigm Shift is the Normal State of Pharmacology. Gurevich VV (2016) EC Pharmacol Toxicol 2(2): 80-85
    › Primary publication · 28936490 (PubMed) · PMC5604476 (PubMed Central)
  9. G protein-coupled receptor kinases as regulators of dopamine receptor functions. Gurevich EV, Gainetdinov RR, Gurevich VV (2016) Pharmacol Res : 1-16
    › Primary publication · 27178731 (PubMed) · PMC5079267 (PubMed Central)
  10. A G Protein-biased Designer G Protein-coupled Receptor Useful for Studying the Physiological Relevance of Gq/11-dependent Signaling Pathways. Hu J, Stern M, Gimenez LE, Wanka L, Zhu L, Rossi M, Meister J, Inoue A, Beck-Sickinger AG, Gurevich VV, Wess J (2016) J Biol Chem 291(15): 7809-20
    › Primary publication · 26851281 (PubMed) · PMC4824988 (PubMed Central)